Abbott India Ltd
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Strength (Total Headcount) Number ・Standalone data |
|
|||||||||||
| Dealers and Distributors Network Number ・Standalone data |
||||||||||||
| Goa Plant Liquid Volume Growth Percentage ・Standalone data |
||||||||||||
| Goa Plant Tablet Volume Growth Percentage ・Standalone data |
||||||||||||
| New Product Launches (Annual) Count ・Standalone data |
||||||||||||
| Dydrogesterone Market Share (Duphaston) Percentage ・Standalone data |
||||||||||||
| Field Force Strength Number ・Standalone data |
||||||||||||
| Share of Products under NLEM Percentage ・Standalone data |
||||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
27 Feb - Abbott to commercialize Novo Nordisk’s semaglutide (Extensior/Ozempic) in India; announced Feb 27, 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 18 Feb
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Feb - Newspaper Publication of the Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2025.
-
Unaudited Financial Results Of The Company For The Quarter Ended December 31, 2025.
12 Feb - Unaudited quarter ended Dec 31, 2025 results approved Feb 12, 2026; Walker Chandiok review attached.
-
Board Meeting Outcome for Outcome Of Board Meeting.
12 Feb - Unaudited Q3/9M results for Dec 31, 2025 approved; Deloitte reappointed internal auditors for FY2026-27.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Sep 2022TranscriptPPTREC
-
Jun 2021TranscriptPPT
Abbott Group
The company is a part of Abbott Laboratories, USA which has a presence in 160 countries with leading medical devices, diagnostics, nutrition products, and branded generic medicines. [1]